Management of Aplastic Anemia and Megaloblastic Anemia

Diagnostic Approach

Diagnosis of aplastic anemia requires comprehensive bone marrow assessment showing severely reduced cellularity (<20% in severe cases), corrected for patient age, according to the American Society of Hematology 1
Bone marrow biopsy in aplastic anemia shows hypocellular marrow with fatty replacement of normal hematopoietic tissue, as reported by the European Hematology Association 2
Blast percentage is below 1% in aplastic anemia, distinguishing it from hypocellular MDS and AML, as stated by the International Society of Hematology 3

Careful monitoring for progression to MDS or AML is necessary in aplastic anemia, as the risk is significantly higher than in the general population, according to the European Hematology Association 3

Misdiagnosis between aplastic anemia and hypocellular MDS/AML can lead to inappropriate treatment, and careful examination of blast percentage and dysplastic features is essential, as emphasized by the American Society of Hematology 4
Age correction is necessary when assessing bone marrow cellularity to avoid misdiagnosis of aplastic anemia, as recommended by the American College of Pathology 1